BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26837337)

  • 1. 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients.
    Sheikhbahaei S; Mena E; Marcus C; Wray R; Taghipour M; Subramaniam RM
    J Nucl Med; 2016 Jun; 57(6):855-60. PubMed ID: 26837337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revalidation of PET/computed tomography criteria (Hopkins criteria) for the assessment of therapeutic response in lung cancer patients: inter-reader reliability, accuracy and survival outcomes.
    Riyami KA; Nuaimi NA; Kliokyte R; Voo S; Thornton A; Bomanji J; Fraioli F
    Nucl Med Commun; 2020 Jan; 41(1):18-25. PubMed ID: 31800507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes.
    Marcus C; Ciarallo A; Tahari AK; Mena E; Koch W; Wahl RL; Kiess AP; Kang H; Subramaniam RM
    J Nucl Med; 2014 Sep; 55(9):1411-6. PubMed ID: 24947059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years.
    Paidpally V; Tahari AK; Lam S; Alluri K; Marur S; Koch W; Wahl RL; Subramaniam RM
    J Nucl Med; 2013 Dec; 54(12):2039-45. PubMed ID: 24101687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features.
    Wray R; Sheikhbahaei S; Marcus C; Zan E; Ferraro R; Rahmim A; Subramaniam RM
    AJR Am J Roentgenol; 2016 Sep; 207(3):641-7. PubMed ID: 27341273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients.
    Antoniou AJ; Marcus C; Tahari AK; Wahl RL; Subramaniam RM
    J Nucl Med; 2014 Jul; 55(7):1062-8. PubMed ID: 24777290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction.
    Sheikhbahaei S; Wray R; Young B; Mena E; Taghipour M; Rahmim A; Subramaniam RM
    Nucl Med Commun; 2016 Mar; 37(3):231-8. PubMed ID: 26575392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
    Marcus C; Marashdeh W; Ahn SJ; Taghipour M; Subramaniam RM
    J Nucl Med; 2015 Jul; 56(7):989-94. PubMed ID: 25952738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival.
    Marcus C; Antoniou A; Rahmim A; Ladenson P; Subramaniam RM
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):281-8. PubMed ID: 25676871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.
    Zhu X; Liao C; Penney BC; Li F; Ferguson MK; Simon CA; Wu T; Liu H; Pu Y
    Nucl Med Commun; 2017 Feb; 38(2):185-192. PubMed ID: 27922540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy.
    Scarsbrook A; Vaidyanathan S; Chowdhury F; Swift S; Cooper R; Patel C
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):581-588. PubMed ID: 27738729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What
    Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
    J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Mazzoletti A; Gazzilli M; Albano D; Giubbini R; Bertagna F
    Indian J Nucl Med; 2022; 37(4):304-309. PubMed ID: 36817208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?
    Tandberg DJ; Gee NG; Chino JP; D'Amico TA; Ready NE; Coleman RE; Kelsey CR
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):796-801. PubMed ID: 23870158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.